|
[Related PubMed/MEDLINE] Total Number of Papers: 30
|
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2023 |
Biological Properties of Heparins Modified with an Arylazopyrazole-Based Photoswitch. |
DS, PS, UFH |
2 |
2022 |
Low Prevalence of Thrombosis Prophylaxis Dose Adjustments Highlights Implications for Patient Safety. |
BMI, PTP, TBW, UFH, VTE |
3 |
2022 |
Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors. |
DTX, SEDDS |
4 |
2021 |
Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-kappaB. |
CBC, CD3, CP, CXCL16, NF-kappaB, PT, TF, TNF-alpha |
5 |
2020 |
A Novel Turn on Fluorescence Sensor for Determination Enoxaparin, a Low Molecular Weight Heparin. |
FL, LMWH |
6 |
2020 |
Comparison of low-molecular-weight heparins in thromboprophylaxis of major orthopaedic surgery - randomized, prospective pilot study. |
Dalt, THR, TKR |
7 |
2018 |
Enoxaparin does not affect network formation of adipose tissue-derived microvascular fragments. |
ad-MVF, GFP, LMWH |
8 |
2018 |
The Efficacy and Safety of Enoxaparin: A Meta-analysis. |
MI, PCI, RCTs, STEMI, UFH |
9 |
2017 |
Passive targeting and lung tolerability of enoxaparin microspheres for a sustained antithrombotic activity in rats. |
MP |
10 |
2017 |
Polysaccharides-based nanocomplexes for the prolonged delivery of enoxaparin: In-vitro and in-vivo evaluation. |
CS, DS, NCs |
11 |
2015 |
Anticoagulant properties of enoxaparin 400IU/mL-40% ethanol catheter lock solution. |
ETP, UFH |
12 |
2012 |
Mesenteric ischemia-reperfusion injury: clearly improved hemodynamics but only minor protection of the rat small intestine by (sub)therapeutic heparin sodium and enoxaparin doses. |
HepSo, SMAO |
13 |
2011 |
Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. |
abx, ASSENT-3 |
14 |
2010 |
Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Abeta levels. |
--- |
15 |
2010 |
Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry. |
AMI, STEMI, UFH |
16 |
2008 |
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. |
GP, UFH |
17 |
2007 |
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. |
STEMI, STRes, UFH |
18 |
2007 |
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. |
CI, MACE, STEMI, UFH |
19 |
2007 |
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. |
RR, UFH |
20 |
2007 |
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. |
PCI, STEMI, UFH |
21 |
2007 |
The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. |
CrCl, STEMI, UFH |
22 |
2007 |
[The safety of enoxaparine use in elderly with acute myocardial infarction]. |
AMI, UFH |
23 |
2005 |
Early postoperative use of unfractionated heparin or enoxaparin is associated with increased surgical re-exploration for bleeding. |
UFH |
24 |
2004 |
Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study). |
ASK, CR, SK, STEMI |
25 |
2003 |
Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. |
CABG, UFH |
26 |
2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. |
UFH |
27 |
2003 |
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. |
ABC, PCI, UFH |
28 |
2003 |
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. |
ABCX, UH |
29 |
2002 |
Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome: a single center experience. |
Dalt, LMWH, NQMI, s.c, UA |
30 |
1998 |
The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. |
Hep, SK |
|